GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

Benzinga Newsdesk www.benzinga.com Positive 80.5%

Neg 0% Neu 0% Pos 80.5%

GSK (NYSE:GSK) FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

Comments

No comments yet. Be the first!